Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma

被引：27

作者：

Ferrucci, Pier Francesco ^{[1
]}

Gandini, Sara ^{[2
]}

Cocorocchio, Emilia ^{[1
]}

Pala, Laura ^{[1
]}

Baldini, Federica ^{[3
]}

Mosconi, Massimo ^{[3
]}

Cappellini, Gian Carlo Antonini ^{[4
]}

Albertazzi, Elena ^{[2
]}

Martinoli, Chiara ^{[1
]}

机构：

[1] European Inst Oncol, Div Med Oncol Melanoma & Sarcoma, Med Oncol Melanoma Unit, Milan, Italy

[2] European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy

[3] European Inst Oncol, Div Surg Melanoma & Sarcoma, Milan, Italy

[4] Ist Dermopat Immacolata IRCCS, Oncol Div 4, Rome, Italy

来源：

ONCOTARGET | 2017年 / 8卷 / 45期

关键词：

eosinophil; predictive; biomarker; ipilimumab; melanoma; TO-LYMPHOCYTE RATIO; METASTATIC MELANOMA; PEMBROLIZUMAB; SURVIVAL; TRIAL;

D O I：

10.18632/oncotarget.19748

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (n = 116) or antiCTLA-4 therapy (n = 128). Visceral involvement, LDH and RLC were associated with prognosis regardless of treatment. Instead, when compared to chemotherapy-treated patients with REC < 1.5%, those with REC >= 1.5% had improved overall survival when receiving anti-CTLA-4 [Hazard Ratio (HR) = 0.56 (0.4-0.93)] but not chemotherapy [HR = 1.13, (0.74-1.74)], and the treatment-by-REC interaction was significant for both overall (p = 0.04) and progression free survival (p = 0.009). These results indicate baseline REC >= 1.5% as a candidate predictive biomarker for benefit from anti-CTLA-4. Further studies are needed to confirm these findings in patients receiving immune-modulating agents.

引用

页码：79809 / 79815

页数：7

共 20 条

[1] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[2] Biomarker: Predictive or Prognostic? [J].

Ballman, Karla V. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) :3968-+

[3] The "cancer immunogram" [J].

Blank, Christian U. ;

Haanen, John B. ;

Ribas, Antoni ;

Schumacher, Ton N. .

SCIENCE, 2016, 352 (6286) :658-660

[4] Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival [J].

Delyon, J. ;

Mateus, C. ;

Lefeuvre, D. ;

Lanoy, E. ;

Zitvogel, L. ;

Chaput, N. ;

Roy, S. ;

Eggermont, A. M. M. ;

Routier, E. ;

Robert, C. .

ANNALS OF ONCOLOGY, 2013, 24 (06) :1697-1703

[5] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab [J].

Ferrucci, P. F. ;

Ascierto, P. A. ;

Pigozzo, J. ;

Del Vecchio, M. ;

Maio, M. ;

Cappellini, G. C. Antonini ;

Guidoboni, M. ;

Queirolo, P. ;

Savoia, P. ;

Mandala, M. ;

Simeone, E. ;

Valpione, S. ;

Altomonte, M. ;

Spagnolo, F. ;

Cocorocchio, E. ;

Gandini, S. ;

Giannarelli, D. ;

Martinoli, C. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :732-738

[6] Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients [J].

Ferrucci, P. F. ;

Gandini, S. ;

Battaglia, A. ;

Alfieri, S. ;

Di Giacomo, A. M. ;

Giannarelli, D. ;

Cappellini, G. C. Antonini ;

De Galitiis, F. ;

Marchetti, P. ;

Amato, G. ;

Lazzeri, A. ;

Pala, L. ;

Cocorocchio, E. ;

Martinoli, C. .

BRITISH JOURNAL OF CANCER, 2015, 112 (12) :1904-1910

[7] Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition [J].

Friedman, Claire F. ;

Postow, Michael A. .

CURRENT ONCOLOGY REPORTS, 2016, 18 (04) :1-7

[8] Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects [J].

Garbe, Claus ;

Eigentler, Thomas K. ;

Keilholz, Ulrich ;

Hauschild, Axel ;

Kirkwood, John M. .

ONCOLOGIST, 2011, 16 (01) :5-24

[9] Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab [J].

Gebhardt, Christoffer ;

Sevko, Alexandra ;

Jiang, Huanhuan ;

Lichtenberger, Ramtin ;

Reith, Maike ;

Tarnanidis, Kathrin ;

Holland-Letz, Tim ;

Umansky, Ludmila ;

Beckhove, Philipp ;

Sucker, Antje ;

Schadendorf, Dirk ;

Utikal, Jochen ;

Umansky, Viktor .

CLINICAL CANCER RESEARCH, 2015, 21 (24) :5453-5459

[10] Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy [J].

Gnjatic, Sacha ;

Bronte, Vincenzo ;

Brunet, Laura Rosa ;

Butler, Marcus O. ;

Disis, Mary L. ;

Galon, Jerome ;

Hakansson, Leif G. ;

Hanks, Brent A. ;

Karanikas, Vaios ;

Khleif, Samir N. ;

Kirkwood, John M. ;

Miller, Lance D. ;

Schendel, Dolores J. ;

Tanneau, Isabelle ;

Wigginton, Jon M. ;

Butterfield, Lisa H. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

← 1 2 →